Research priorities in pharmacokinetics.
作者信息
Tucker Geoffrey T
机构信息
Simcyp Ltd, Blades Enterprise Centre, John St, Sheffield S24SU, UK.
出版信息
Br J Clin Pharmacol. 2012 Jun;73(6):924-6. doi: 10.1111/j.1365-2125.2012.04238.x.
Abstract
An opinion is expressed on the past, present and future roles of pharmacokinetic-pharmacodynamic research in the context of UK clinical pharmacology. On the basis of its current constitution, it seems unlikely that this area of research will be driven from within academic clinical pharmacology in the UK. Therefore, in order to bring its expertise and experience to bear effectively on the evolving emphasis on translational medicine and modelling and simulation, this community would need to reach out beyond its current preoccupations to increase interactions with the next generation of pharmacokineticists and pharmacometricians.
摘要
相似文献
1
Research priorities in pharmacokinetics.
Br J Clin Pharmacol. 2012 Jun;73(6):924-6. doi: 10.1111/j.1365-2125.2012.04238.x.
2
Pediatric pharmacology: current efforts and future goals to improve clinical practice.儿科药理学：改善临床实践的当前努力与未来目标
Expert Opin Drug Metab Toxicol. 2015;11(11):1679-82. doi: 10.1517/17425255.2015.1065815. Epub 2015 Jul 13.
3
Expanding clinical applications of population pharmacodynamic modelling.拓展群体药效学模型的临床应用
Br J Clin Pharmacol. 1998 Oct;46(4):321-33. doi: 10.1046/j.1365-2125.1998.00792.x.
4
The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics.基于机制的药代动力学-药效学（PK-PD）建模在生物制品转化研究中的作用。
Drug Discov Today. 2007 Dec;12(23-24):1018-24. doi: 10.1016/j.drudis.2007.10.002. Epub 2007 Nov 19.
5
Qualitative pharmacokinetic modeling of drugs.药物的定性药代动力学建模
AMIA Annu Symp Proc. 2005;2005:71-5.
6
Training the next generation of pharmacometric modelers: a multisector perspective.培养下一代药代动力学建模师：多部门视角。
J Pharmacokinet Pharmacodyn. 2024 Feb;51(1):5-31. doi: 10.1007/s10928-023-09878-4. Epub 2023 Aug 13.
7
Impact of pharmacokinetic-pharmacodynamic modelling in early clinical drug development.药代动力学-药效学模型在早期临床药物开发中的影响。
Eur J Pharm Sci. 2017 Nov 15;109S:S53-S58. doi: 10.1016/j.ejps.2017.05.042. Epub 2017 May 20.
8
Pharmacokinetic/pharmacodynamic modeling in drug research and development.药物研发中的药代动力学/药效学建模
J Clin Pharmacol. 2000 Dec;40(12 Pt 2):1399-418.
9
Modelling during drug development.
Eur J Pharm Biopharm. 2000 Jul;50(1):13-26. doi: 10.1016/s0939-6411(00)00083-7.
10
Introduction of quantitative methods in pharmacology and clinical pharmacology: a historical overview.药理学与临床药理学中定量方法的引入：历史概述
Clin Pharmacol Ther. 2007 Jul;82(1):3-6. doi: 10.1038/sj.clpt.6100248.
引用本文的文献
1
Challenges and opportunities in the advancement of nanomedicines.纳米医药发展的挑战与机遇。
J Control Release. 2012 Dec 10;164(2):236-46. doi: 10.1016/j.jconrel.2012.10.007. Epub 2012 Oct 12.
本文引用的文献
1
Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review.在监管审查期间，生理基于药代动力学（PBPK）建模和模拟的应用。
Clin Pharmacol Ther. 2011 Feb;89(2):259-67. doi: 10.1038/clpt.2010.298. Epub 2010 Dec 29.
2
Quantitative clinical pharmacology is transforming drug regulation.定量临床药理学正在改变药物监管。
J Pharmacokinet Pharmacodyn. 2010 Dec;37(6):617-28. doi: 10.1007/s10928-010-9171-3. Epub 2010 Oct 27.
3
Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses.细胞色素 P450 检测在精神分裂症成人抗精神病药物处方中的应用：系统评价和荟萃分析。
Pharmacogenomics J. 2011 Feb;11(1):1-14. doi: 10.1038/tpj.2010.73. Epub 2010 Sep 28.
4
Physiologically-based pharmacokinetics in drug development and regulatory science.生理药代动力学在药物研发和监管科学中的应用。
Annu Rev Pharmacol Toxicol. 2011;51:45-73. doi: 10.1146/annurev-pharmtox-010510-100540.
5
Predictions of the ADMET properties of candidate drug molecules utilizing different QSAR/QSPR modelling approaches.利用不同的定量构效关系/定量构性关系建模方法预测候选药物分子的 ADMET 性质。
Curr Drug Metab. 2010 May;11(4):285-95. doi: 10.2174/138920010791514306.
6
Simulation for clinical research trials: a theoretical outline.临床研究试验模拟：理论概述。
J Crit Care. 2009 Jun;24(2):164-7. doi: 10.1016/j.jcrc.2009.01.009. Epub 2009 Mar 27.
7
Modelling methods for pharmacoeconomics and health technology assessment: an overview and guide.药物经济学与卫生技术评估的建模方法：概述与指南
Pharmacoeconomics. 2008;26(2):131-48. doi: 10.2165/00019053-200826020-00004.
8
Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis.基于机制的药代动力学-药效学建模：生物相分布、受体理论和动力学系统分析。
Annu Rev Pharmacol Toxicol. 2007;47:357-400. doi: 10.1146/annurev.pharmtox.47.120505.105154.
9
Editorial: Pharmacokinetics--master or servant?
Eur J Clin Pharmacol. 1973 Jun;6(1):1-2. doi: 10.1007/BF00561792.
10
The value of therapeutic drug monitoring to the practising physician--an hypothesis in need of testing.治疗药物监测对执业医师的价值——一个有待检验的假设。
Br J Clin Pharmacol. 1989 Mar;27(3):281-4. doi: 10.1111/j.1365-2125.1989.tb05365.x.
Zotero 插件